South Korea’s Enzychem Has a Lifesaver for Cadila’s COVID-19 Shot
Bengali language:
South Korea’s Enzychem Lifesciences will produce at least 80 million doses of India’s homegrown COVID-19 DNA vaccine from Cadila Healthcare, the domestic drugmaker said on Wednesday.
As part of the agreement, Cadila will transfer DNA vaccine technology to Enzychem, which will manufacture and sell the vaccine, ZyCoV-D, in its territory under the Cadila brand. Cadila will receive licensing fees and royalty payments, the company said in an application posted to https://bit.ly/3HZz3a2 on stock exchanges.
Ki Young Sohn, President of Enzychem Lifesciences, said, “DNA technology enables the production of vaccines at a reasonable cost in record time and a remarkably stable DNA vaccine,” said Ki Young Sohn, president of Enzychem. Lifesciences said.
“ZyCoV-D is used without a needle and can be deployed more easily, especially in resource-poor populations.”
The Cadila vaccine, which uses three doses, was approved by the country’s drug regulator in August for emergency use in adults and children 12 years of age and older, although it has yet to be developed. declared as part of the county immunization program.
(Except for the title, this story has not been edited by NDTV staff and is published from an aggregated feed.)